PhIII prostate cancer failure forces deep job cuts at Active Biotech

Just 6 weeks after seeing disappointing data from its Phase III study of tasquinimod for prostate cancer, Sweden's Active Biotech is laying off 47 staffers, leaving only 9 employees at the company. The drug delayed disease progression but failed to achieve an improvement in overall survival, forcing Ipsen out of their collaboration. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.